NeurOp is a preclinical stage drug discovery company advancing next generation small molecule therapeutics for CNS indications such as depression, pain and ischemia. The firms technology is based on their development of a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Our compounds specifically target the NR2B subtype of these receptors, offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy. The NMDA receptor blocker has a leading role in treating major depression, neuropathic pain, ischemia and other disorders, such as schizophrenia and Parkinsons disease.
